INCA33890

DRUG4 trials

Sponsors

Incyte Corp., Incyte Corporation

Conditions

Advanced Solid TumorsCRC (Colorectal Cancer)Metastatic Microsatellite Stable Colorectal CancerMetastatic Solid TumorsSolid Tumors

Phase 1

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

RecruitingNCT05836324

Incyte CorporationAdvanced Solid Tumors, Metastatic Solid Tumors, Solid Tumors

Start: 2023-07-24End: 2027-01-13Target: 408Updated: 2025-12-18

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

RecruitingNCT06179160

Incyte CorporationSolid Tumors

Start: 2024-01-04End: 2027-01-01Target: 710Updated: 2026-05-04

Phase 3

A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

RecruitingNCT07284849

Incyte CorporationCRC (Colorectal Cancer)

Start: 2026-03-05End: 2029-09-28Target: 700Updated: 2026-05-08

A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Not yet recruitingCTIS2025-523735-19-00

Incyte Corp.Metastatic Microsatellite Stable Colorectal Cancer

Target: 106Updated: 2026-05-20

Related Papers

Abstract 7775: Pharmacodynamic biomarkers of TGFβR2xPD-1 bispecific antibody INCA33890 in patients with MSS metastatic colorectal cancer (mCRC)

Cancer Research2026-04-03

Preliminary phase 1 results of INCB161734, a novel oral Kirsten rat sarcoma (KRAS) G12D inhibitor, as monotherapy or in combination with chemotherapy for advanced/metastatic pancreatic duct adenocarcinoma (PDAC).

Journal of Clinical Oncology2026-01-10

Baseline biomarker analysis and clinical outcomes of the PD-1/TGFβR2 bispecific antibody INCA33890 in patients with non-MSI-H metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2026-01-10

Abstract 6074: INCA33890, a bispecific antibody targeting PD-1 and TGFβR2, shows enhanced immune responses in models of ovarian cancer

Cancer Research2025-04-21